Read the full press release HERE
Vaaji today announced the successful completion of its pilot study, demonstrating 100 % accuracy in its IoT-enabled Smart Patch’s remote detection of transdermal patch application. In collaboration with the Penn Artificial Intelligence and Technology Collaboratory at University of Pennsylvania, the proof-of-concept trial enrolled 51 healthy volunteers using placebo patches to validate the system’s ability to detect correct application, missed doses, or incorrect “patch stacking.” The results confirm perfect agreement between remote monitoring data and onsite investigator records, matching the “gold standard” of direct human oversight.
The exploratory study, part of the AI/Tech + Aging (A2) Collective funded by the National Institute on Aging (NIA), delivered real-time visibility into patch status through embedded sensors and data analysis — without requiring clinician intervention. The Smart Patch platform offers a powerful tool to reduce medication errors, prevent overdoses, and support safe use of transdermal therapies (e.g., for Alzheimer’s, Parkinson’s, pain management). The technology proved usable in volunteers’ daily routines, reinforcing its readiness for home-based care and further clinical development.